Immunoglobulin G Monoclonal Antibodies toCryptococcus neoformansProtect Mice Deficient in Complement Component C3
Open Access
- 1 May 2002
- journal article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 70 (5) , 2598-2604
- https://doi.org/10.1128/iai.70.5.2598-2604.2002
Abstract
Passive administration of monoclonal antibodies (MAbs) to the capsular polysaccharide of Cryptococcus neoformans can alter the course of infection in mice. In a murine model of cryptococcal infection, immunoglobulin G1 (IgG1), IgG2a, and IgG2b switch variants of the anti-capsular 3E5 MAb prolong the survival of lethally infected mice, whereas the 3E5 IgG3 MAb does not protect and in some cases enhances infection, shortening the life spans of infected mice. We examined the role of complement component C3 in Ab-mediated protection by determining the efficacy of the four mouse IgG subclasses against C. neoformans in mice genetically deficient in factor C3 as well as mice acutely depleted of C3. Similar to other complement-deficient animal models, C3−/− mice and mice depleted of C3 by cobra venom factor were more susceptible to C. neoformans infection than control mice, providing further evidence that complement is important in the host defense against the fungus. In the absence of C3, all IgG isotypes prolonged the lives of mice infected with C. neoformans, indicating that protection by IgG does not require the complement pathways. Furthermore, we observed protection with IgG3 in the complement-deficient mice, suggesting that complement is involved in the lack of protection observed with IgG3 in other mouse models.Keywords
This publication has 95 references indexed in Scilit:
- Both Th1 and Th2 Cytokines Affect the Ability of Monoclonal Antibodies To Protect Mice againstCryptococcus neoformansInfection and Immunity, 2001
- CR3‐dependent phagocytosis by murine macrophages: different cytokines regulate ingestion of a defined CR3 ligand and complement‐opsonized Cryptococcus neoformansImmunology, 1997
- Epitope Location in the Cryptococcus neoformans Capsule Is a Determinant of Antibody EfficacyThe Journal of Experimental Medicine, 1997
- Immunoglobulin G3 blocking antibodies to the fungal pathogen Cryptococcus neoformans.The Journal of Experimental Medicine, 1996
- Combination of 5-flucytosine and capsule-binding monoclonal antibody in the treatment of murine Cryptococcus neoformans infections and in vitroJournal of Antimicrobial Chemotherapy, 1996
- Estimation of the Prevalence of Cryptococcal Infection Among Patients Infected with the Human Immunodeficiency Virus in New York CityClinical Infectious Diseases, 1994
- Antibodies Elicited by a Cryptococcus neoformans-Tetanus Toxoid Conjugate Vaccine Have the Same Specificity as Those Elicited in InfectionThe Journal of Infectious Diseases, 1992
- Overview of Host Defenses in Fungal InfectionsClinical Infectious Diseases, 1992
- The fifth component of complement (C5) in the mouse. Analysis of the molecular basis for deficiency.The Journal of Experimental Medicine, 1987
- A new Fc receptor on mouse macrophages binding IgG3.The Journal of Experimental Medicine, 1981